Full Press Release Details
Fresenius Medical Care
Investor News Fresenius Medical Care AG & Co. KGaA
Phone: + 49 6172 609 2601
Fax: + 49 6172 609 2301
E-mail: ir@fmc-ag.com
Phone: + 1 781 402 9000
Fax: + 1 781 402 9741
E-mail: ir@fmc-ag.com
Internet: http://www.fmc-ag.com
---------------------
Fresenius Medical Care Successfully Completes the Conversion
of Preference Shares and the Transformation into KGaA
Bad Homburg, Germany - February 13, 2006 - Fresenius Medical Care AG & Co. KGaA
("the Company") (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS-p), the
world's largest provider of Dialysis Products and Services, today announced the
completion of the conversion of preference shares into ordinary shares and the
transformation of the legal form of the Company from an Aktiengesellschaft into
a partnership limited by shares (Kommanditgesellschaft auf Aktien - KGaA). The
transformation and the conversion have become effective upon registration with
the commercial register of the local court (Amtsgericht), in Hof an der Saale
(Germany) on Friday evening, February 10, 2006. All Shareholders in former
Fresenius Medical Care AG have now become shareholders in Fresenius Medical Care
AG & Co. KGaA. The new ordinary shares which resulted from the conversion will
start trading today.
Fresenius Medical Care AG & Co. KGaA, February 13, 2006 1 of 2
As of February 10, 2006, the share capital of Fresenius Medical Care AG & Co.
KGaA amounts to (euro)250,271,178.24 consisting of 96,629,422 ordinary bearer
shares and 1,132,757 non-voting preference bearer shares which have not been
converted within the conversion offer.
Ben Lipps, Chief Executive Officer of Fresenius Medical Care, commented: "I am
very pleased that we completed both, the conversion and the change of the legal
form. With that we have fulfilled the mandate of the extraordinary shareholder
meeting on August 30, 2005. The conversion and the change of the legal form of
our Company are major steps towards enhancing the attractiveness of our shares
and in providing flexibility for future growth opportunities for the benefit of
Fresenius Medical Care is the world's largest, integrated provider of products
and services for individuals undergoing dialysis because of chronic kidney
failure, a condition that affects more than 1,300,000 individuals worldwide.
Through its network of approximately 1,670 dialysis clinics in North America,
Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides
dialysis treatment to approximately 130,400 patients around the globe. Fresenius
Medical Care is also the world's leading provider of dialysis products such as
hemodialysis machines, dialyzers and related disposable products.
For more information about Fresenius Medical Care visit the Company's website at
This release contains forward-looking statements that are subject to various
risks and uncertainties. Actual results could differ materially from those
described in these forward-looking statements due to certain factors, including
changes in business, economic and competitive conditions, regulatory reforms,
foreign exchange rate fluctuations, uncertainties in litigation or investigative
proceedings, and the availability of financing. These and other risks and
uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports
filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care
AG & Co. KGaA does not undertake any responsibility to update the
forward-looking statements in this release.
Fresenius Medical Care AG & Co. KGaA, February 13, 2006 2 of 2